Document Detail


Influence of mother and infant zidovudine treatment duration on the age at which HIV infection can be detected by polymerase chain reaction in infants.
MedLine Citation:
PMID:  15134179     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To investigate the influence of zidovudine (ZDV) prophylaxis duration in mothers and infants on the age at which infection becomes detectable by DNA polymerase chain reaction (PCR) in non-breastfed infants. METHODS: Blood samples were collected sequentially from birth to 6 months in a Thailand perinatal HIV prevention trial in which 98 transmissions occurred. The proportions of infections detectable at birth and the Turnbull distributions of age at which infection became detectable after birth were compared according to actual ZDV treatment duration (mothers: no more than 7.5 weeks versus more; infants: 3 days versus at least 4 weeks), provided an adherence greater than 75%. RESULTS: Detectable infection at birth was less frequent in children whose mothers received a long treatment as compared to a short treatment (27 vs 50%, P=0.04). When mothers received a long treatment, infant ZDV treatment duration did not influence the distribution of age at which infection became detectable after birth (median 24 days). However, when mothers received a short treatment, this distribution was shifted to the right when infants received a long treatment (median 43 days, P<0.0001), and to the left when infants received a short treatment (median 11 days, P<0.0001). CONCLUSIONS: When mothers receive a short treatment, the proportion of infections detectable at birth is higher and the time at which infection becomes detectable after birth depends on the infant treatment duration. In the study conditions, a PCR result after 2 months could be used to define infection status.
Authors:
Sukon Prasitwattanaseree; Marc Lallemant; Dominique Costagliola; Gonzague Jourdain; Jean-Yves Mary
Related Documents :
16916459 - Abo phenotypes and malaria related outcomes in mothers and babies in the gambia: a role...
2548469 - Morbidity from acquired cytomegalovirus infection in a neonatal intensive care unit.
7664179 - Development of interleukin 6 and tumor necrosis factor alpha activity in nasopharyngeal...
2937029 - Erythema multiforme in childhood and early infancy.
1437359 - Urinary tract infection in infants in spite of prenatal diagnosis of hydronephrosis.
6416019 - Sequential determination of crp, alpha 1-antitrypsin and haptoglobin in neonatal septic...
23528249 - Very low birth weight preterm infants are at risk for hypoglycemia once on total entera...
17142119 - Parenteral amino acid and energy administration to premature infants in early life.
23024609 - 5-month-olds' categorization of novel objects: task and measure dependence.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Antiviral therapy     Volume:  9     ISSN:  1359-6535     ISO Abbreviation:  Antivir. Ther. (Lond.)     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-05-11     Completed Date:  2004-06-28     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9815705     Medline TA:  Antivir Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  179-85     Citation Subset:  IM    
Affiliation:
INSERM ERM 0321, University Paris 7-Denis Diderot, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age of Onset
Anti-HIV Agents / administration & dosage*,  therapeutic use
Chemoprevention
Double-Blind Method
Drug Administration Schedule
Female
HIV Infections / drug therapy*,  prevention & control,  virology
HIV-1 / genetics,  isolation & purification*
Humans
Infant
Infant, Newborn
Infectious Disease Transmission, Vertical / prevention & control
Polymerase Chain Reaction / methods*
Pregnancy
Pregnancy Complications, Infectious / drug therapy*,  virology
Prospective Studies
Reverse Transcriptase Inhibitors / administration & dosage*,  therapeutic use
Zidovudine / administration & dosage*,  therapeutic use
Grant Support
ID/Acronym/Agency:
R01 HD 33326/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Reverse Transcriptase Inhibitors; 30516-87-1/Zidovudine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alte...
Next Document:  Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study.